The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
(10 - 33) Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21.10 - Manufacture of basic pharmaceutical products
5,000 jobs Number of planned job losses
Announcement Date
10 September 2025
Employment effect (start)
10 December 2025
Foreseen end date
Description
Novo Nordisk has announced a major restructuring involving the dismissal of approximately 9,000 employees globally, with 5,000 of those in Denmark: Novo Nordisk 2025 - WO. The layoffs represent around 14% of the company’s workforce in Denmark.
The restructuring aims to free up resources for growth in diabetes and obesity treatments. The restructuring includes one-off costs of DKK 8 billion in 2025, leading to revised profit expectations. Despite the scale of the cuts, the market responded positively, viewing the move as a sign of strategic decisiveness. Novo’s stock rose 3.7% following the announcement.
Eurofound (2025), Novo Nordisk, Internal restructuring in Denmark, factsheet number 203295, European Restructuring Monitor. Dublin, https://dev.eurofound.europa.eu/restructuring-events/detail/203295.
Digitisation and automation technologies, including artificial intelligence (AI), can affect working conditions in a variety of ways and their use in the workplace raises a host of new ethical concerns.
The retail banking sector is fertile ground for studying the impacts of digitalisation on work and employment. Financial services are increasingly provided online, without the intermediary of customer-facing institutions.
European labour markets have recovered strongly from COVID-19. By the end of 2021, little more than 18 months after the start of the pandemic, employment rates in the EU were almost at pre-crisis levels.
